Haruna L. Barazorda-Ccahuana

Mrs. Haruna L. Barazorda-Ccahuana

Universidad Católica de Santa María de Arequipa, Arequipa, Peru
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2019 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
CPCarla A. Paredes-Rosan
Carla A. Paredes-Rosan
DVDiego E. Valencia
Diego E. Valencia
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
JAJorge Alberto Aguilar-Pineda
Jorge Alberto Aguilar-Pineda
Badhin GómezBadhin Gómez
Badhin Gómez

1 June 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Maria Natalia CalienniMaria Natalia Calienni
Maria Natalia Calienni
CFCamilo Febres-Molina
Camilo Febres-Molina
RLRamiro Esteban Llovera
Ramiro Esteban Llovera
CZChristian Zevallos-Delgado
Christian Zevallos-Delgado
MTMaría Eugenia Tuttolomondo
María Eugenia Tuttolomondo
Jorge MontanariJorge Montanari
Jorge Montanari

9 January 2023 in Nature Sustainability
Verified
Journal Article
Closed access
PDF file
ASAlexsandro Dos Santos
Alexsandro Dos Santos
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
GCGriselda Caballero-Manrique
Griselda Caballero-Manrique
YCYvens CHEREMOND
Yvens CHEREMOND
PEPatricio Javier Espinoza-Montero
Patricio Javier Espinoza-Montero
Sergi Garcia-SeguraSergi Garcia-Segura
Sergi Garcia-Segura

25 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
KAREL MENA ULECIAKAREL MENA ULECIA
KAREL MENA ULECIA
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
(1) Background: The COVID-19 pandemic lacks treatments; for this reason, the search for potential compounds against therapeutic targets is still necessary. Bioinformatics tools have allowed the rapid in silico screening of possible new metabolite candidates from natural resources or repurposing known ones. Thus, in this work, we aimed to select phytochemical candidates from Peruvian plants with antiviral potential against three therapeutical targets of SARS-CoV-2. (2) Methods: We applied in silico technics, such as virtual screening, molecular docking, molecular dynamics simulation, and MM/GBSA estimation. (3) Results: Rutin, a compound present in Peruvian native plants, showed affinity against three targets of SARS-CoV-2. The molecular dynamics simulation demonstrated the high stability of receptor–ligand systems during the time of the simulation. Our results showed that the Mpro-Rutin system exhibited higher binding free energy than PLpro-Rutin and N-Rutin systems through MM/GBSA analysis. (4) Conclusions: Our study provides insight on natural metabolites from Peruvian plants with therapeutical potential. We found Rutin as a potential candidate with multiple pharmacological properties against SARS-CoV-2.

30 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Alejandro Gómez GarcíaAlejandro Gómez García
Alejandro Gómez García
DJDaniel Alonso Acuña Jiménez
Daniel Alonso Acuña Jiménez
WZWilliam J. Zamora
William J. Zamora
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
JMJose Medina-Franco
Jose Medina-Franco
The number of databases of natural products (NPs) has increased substantially. Latin America is extraordinarily rich in biodiversity, enabling the identification of novel NPs, which has encouraged both the development of databases and the implementation of those that are being created or are under development. In a collective effort from several Latin American countries, herein we introduce the first version of the Latin American Natural Products Database (LANaPDB), a public compound collection that gathers the chemical information of NPs contained in diverse databases from this geographical region. The current version of LANaPDB unifies the information from six countries and contains 12,959 chemical structures. The structural classification showed that the most abundant compounds are the terpenoids (63.2%), phenylpropanoids (18%) and alkaloids (11.8%). From the analysis of the distribution of properties of pharmaceutical interest, it was observed that many LANaPDB compounds satisfy some drug-like rules of thumb for physicochemical properties. The concept of the chemical multiverse was employed to generate multiple chemical spaces from two different fingerprints and two dimensionality reduction techniques. Comparing LANaPDB with FDA-approved drugs and the major open-access repository of NPs, COCONUT, it was concluded that the chemical space covered by LANaPDB completely overlaps with COCONUT and, in some regions, with FDA-approved drugs. LANaPDB will be updated, adding more compounds from each database, plus the addition of databases from other Latin American countries.

28 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
KAKarla L. F. Alvarez
Karla L. F. Alvarez
JAJorge Alberto Aguilar-Pineda
Jorge Alberto Aguilar-Pineda
CCchristian lino cardenas
christian lino cardenas
Background: Despite research on the molecular bases of Alzheimer’s disease (AD), effective therapies against its progression are still needed. Recent studies have shown direct links between AD progression and neurovascular dysfunction, highlighting it as a potential target for new therapeutics development. In this work, we screened and evaluated the inhibitory effect of natural compounds from native Peruvian plants against tau protein, amyloid beta, and angiotensin II type 1 receptor (AT1R) pathologic AD markers. Methods: We applied in silico analysis, such as virtual screening, molecular docking, molecular dynamics simulation (MD), and MM/GBSA estimation, to identify metabolites from Peruvian plants with inhibitory properties, and compared them to nicotinamide, telmisartan, and grapeseed extract drugs in clinical trials. Results: Our results demonstrated the increased bioactivity of three plants’ metabolites against tau protein, amyloid beta, and AT1R. The MD simulations indicated the stability of the AT1R:floribundic acid, amyloid beta:rutin, and tau:brassicasterol systems. A polypharmaceutical potential was observed for rutin due to its high affinity to AT1R, amyloid beta, and tau. The metabolite floribundic acid showed bioactivity against the AT1R and tau, and the metabolite brassicasterol showed bioactivity against the amyloid beta and tau. Conclusions: This study has identified molecules from native Peruvian plants that have the potential to bind three pathologic markers of AD.